Loading...
•
Mar 31, 2022
OPKO Health Q1 2022 Earnings Report
Reported first quarter business highlights and financial results.
Key Takeaways
OPKO Health reported consolidated total revenues of $329.2 million for the first quarter of 2022, compared to $545.2 million for the comparable period in 2021. The operating loss for the first quarter of 2022 was $72.4 million, compared to an operating income of $38.5 million for the 2021 quarter. Net loss for the first quarter of 2022 was $55.4 million, or $0.08 per share, compared to net income of $31.1 million, or $0.05 per diluted share, for the 2021 quarter.
Acquired ModeX Therapeutics, Inc., gaining proprietary immunotherapy technology and new executives.
Completed the sale of GeneDx LLC to Sema4 Holdings Corp.
Pfizer launched NGENLA® (Somatrogon) injection in Germany, Japan, and additional markets, triggering $85 million in milestone payments for OPKO.
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) launched RAYALDEE® in Germany and subsequently in Switzerland.
Forward Guidance
OPKO’s senior management will provide a business update, discuss first quarter financial results and the ModeX acquisition.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...